Zimmer Partners LP bought a new stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 22,500 shares of the company’s stock, valued at approximately $495,000. Zimmer Partners LP owned 0.09% of Terns Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently bought and sold shares of TERN. UBS Group AG bought a new position in Terns Pharmaceuticals during the 1st quarter valued at about $56,000. New York State Common Retirement Fund bought a new position in shares of Terns Pharmaceuticals in the 1st quarter worth approximately $86,000. American International Group Inc. bought a new position in shares of Terns Pharmaceuticals in the 1st quarter worth approximately $112,000. California State Teachers Retirement System bought a new position in shares of Terns Pharmaceuticals in the 1st quarter worth approximately $289,000. Finally, Nuveen Asset Management LLC bought a new position in shares of Terns Pharmaceuticals in the 1st quarter worth approximately $310,000. Institutional investors and hedge funds own 71.22% of the company’s stock.
Separately, Zacks Investment Research upgraded shares of Terns Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday.
Terns Pharmaceuticals (NASDAQ:TERN) last released its earnings results on Thursday, May 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.35). As a group, analysts predict that Terns Pharmaceuticals, Inc. will post -3.54 EPS for the current fiscal year.
Terns Pharmaceuticals Company Profile
Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH.
Read More: Does the discount rate affect the economy?
Want to see what other hedge funds are holding TERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Terns Pharmaceuticals, Inc. (NASDAQ:TERN).
Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.